Alltrna
Alltrna is pioneering the development of universal tRNA medicines to treat a wide range of diseases caused by genetic mutations. Utilizing a unique platform that incorporates AI and machine learning, Alltrna aims to restore protein production disrupted by these mutations. Their innovative approach allows for the creation of programmable tRNA therapeutics, which can address multiple diseases with shared genetic underpinnings. The company is positioned at the forefront of genetic medicine, focusing on conditions caused by nonsense mutations, and has demonstrated significant advancements in the field, including successful preclinical data and substantial funding to support its mission.
Alltrna
Alltrna is pioneering the development of universal tRNA medicines to treat a wide range of diseases caused by genetic mutations. Utilizing a unique platform that incorporates AI and machine learning, Alltrna aims to restore protein production disrupted by these mutations. Their innovative approach allows for the creation of programmable tRNA therapeutics, which can address multiple diseases with shared genetic underpinnings. The company is positioned at the forefront of genetic medicine, focusing on conditions caused by nonsense mutations, and has demonstrated significant advancements in the field, including successful preclinical data and substantial funding to support its mission.
TL;DR
Company: Alltrna — tRNA medicines company
Founded: 2018
Head investor / founder: Flagship Pioneering
Total funding: USD 159,000,000
Lead program focus: Programmable tRNA therapeutics for diseases caused by premature termination codons
Company Overview
Problem Domain
Genetic diseases caused by premature termination codons and other shared mutations (stop codon disease).
Founded
2018
Industry
Biotechnology
Tech Stack
Funding Track Record
USD 109,000,000
Announced to advance tRNA medicines for stop codon disease
Investor Signal
“Flagship Pioneering is the company's founder and a lead/backing investor”